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ABSTRACT
Objective To determine how the first wave of 
the COVID-19 pandemic affected outcomes for all 
operatively managed neurosurgical patients, not only 
those positive for SARS- CoV-2.
Design Matched cohort (pairwise method).
Setting A single tertiary neurosurgical referral centre at a 
large UK Major Trauma Centre.
Participants During the first COVID-19 wave, 231 
neurosurgical cases were performed. These cases 
were matched to cases from 2019. Cases were 
matched for age (±10 years), primary pathology and 
surgical procedure. Cases were excluded from analysis 
if either the age could not be matched to within 10 
years, or the primary pathology or procedure was too 
unique. After exclusions, 191 cases were included in 
final analysis.
Outcome measures Primary outcomes were 30- day 
mortality and postoperative pulmonary complications. 
Secondary outcomes included Glasgow Outcome Score 
(GOS) on discharge, length of stay (LoS), operative and 
anaesthetic times and grade of primary surgeon. An 
exploratory outcome was the SARS- CoV-2 status of 
patients.
Results There was no significant difference between 
the pandemic and matched cohorts in 30- day mortality, 
pulmonary complications, discharge GOS, LoS, 
operative or anaesthetic times. There was a significant 
difference in the variation of grade of primary surgeon. 
Only 2.2% (n=5) of patients had a SARS- CoV-2 positive 
swab.
Conclusion During the first UK wave of the COVID-19 
pandemic, the mortality, morbidity and functional 
outcomes of operatively managed neurosurgical patients 
at University Hospitals Birmingham were not significantly 
affected compared with normal practice. The grade of 
primary surgeon was significantly more senior and adds 
to the growing body of evidence that demonstrates 
how the pandemic has negatively impacted UK surgical 
training. Mixing COVID-19 positive, unknown and 
negative cases did not significantly impact on outcomes 
and indicates that further research is required to 
support the implementation of evidence- based surgical 
pathways, such as COVID- light sites, throughout the next 
stage of the pandemic.
INTRODUCTION
Background and rationale
The first cases of COVID-19 were diagnosed 
in the UK at the end of January 2020.1 
Hospitals began to prepare for the antici-
pated influx of severely unwell patients and 
surgical departments were advised to adapt 
their protocols, create additional capacity 
and protect their vulnerable patient groups. 
By mid- March, neurosurgical elective proce-
dures were cancelled at the University Hospi-
tals Birmingham (UHB) Foundation Trust. 
Exceptions were cancer, life- limiting cases or 
cases that ran a high risk of significant dete-
rioration within 2 weeks if left untreated.2 
Neuro- theatre capacity was reduced to one 
theatre running 24 hours a day and an addi-
tional ad hoc emergency daytime list where 
neuro- anaesthetic support allowed. These 
changes were necessary as UHB became 
the Trust ‘worst hit’ by COVID-193 with the 
Office for National Statistics confirming that 
Birmingham had the highest peak excess 
mortality of any major British city at 249.7%.4
Strengths and limitations of this study
 ► This is the first study to individually match neuro-
surgical cases performed during the first pandem-
ic wave to cases performed under ‘pre- pandemic’ 
conditions.
 ► Primary outcomes have been designed to be compa-
rable with prior international surgical cohort studies.
 ► The numbers of patients analysed are small and 
from a single unit only.
 ► Not all neurosurgical cases performed during the 
first pandemic phase could be matched to pre- 
pandemic cases.
 ► Given the evolving understanding of the virus during 
the first wave, there was no universal swabbing pro-
tocol that could be applied to all cases in the pan-
demic cohort.
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While there have been several studies published on 
the restructuring of neurosurgery services and impact 
of COVID-19 on workload,5–7 there is currently limited 
evidence as to the impact of COVID-19 on the outcomes 
that such changes have had for neurosurgical patients. In 
May 2020, the COVIDSurg collaborative determined that 
postoperative pulmonary complications occur in 50.0% 
of neurosurgical patients with perioperative SARS- CoV-2 
infection and 30- day mortality was 18.4%.8 A US group 
reported the incidence of COVID-19 in neurosurgical 
patients to be 5.4% with a higher rate of complications in 
positive patients compared with negative patients.9 While 
it is vital to gather evidence on how SARS- CoV-2 affects the 
outcome of infected neurosurgical patients, the majority 
of patients (almost 95%) remain uninfected.9 There is 
currently no evidence to describe how the pandemic has 
affected the outcome of the entire neurosurgical cohort 
when compared with ‘normal’ neurosurgical practice.
This study compares the outcomes of patients under-
going neurosurgical procedures during the height of the 
pandemic against a matched cohort from prior to the 
COVID-19 outbreak.
Objectives
1. To compare the rates of 30- day mortality and pulmo-
nary complications.
2. To compare functional outcome and length of hospital 
stay (LoS).
3. To compare anaesthetic and operative factors.
4. To determine rates of patients screened for COVID-19, 
incidence of confirmed cases and their clinical course.
MATERIALS AND METHODS
Study design
The study was undertaken at the Queen Elizabeth Hospital 
Birmingham (QEHB) as a single- centre, matched cohort 
study. The QEHB is the largest hospital within the UHB 
Foundation Trust, is one of three regional adult neuro-
surgical units in the West Midlands, and is responsible for 
a mixed urban and rural population.
Participants
Operations performed during the initial stage of the 
pandemic (19 March 2020–1 June 2020) were matched 
to pre- pandemic cases (11 March 2019–11 September 
2019). The pandemic time period was chosen as this 
was the interval in which elective neurosurgery cases 
at UHB were cancelled and will be referred to as the 
‘initial pandemic phase’ from here onwards. Cases were 
matched in a pairwise fashion for age at time of proce-
dure (±10 years), primary pathology and procedure. 
Primary pathology included severity where appropriate; 
for example, poor grade subarachnoid haemorrhage 
(SAH) was matched with another SAH of equivalent 
poor grade. Procedure was also matched to site where 
significant; for example a left- sided frontal craniotomy 
was matched with another left- sided frontal craniotomy 
rather than a right- sided. Ward- based procedures such 
as lumbar drain and intracranial pressure bolt insertion 
were not included. Cases were deemed unmatchable and 
were excluded from analysis if either the age could not be 
matched to within 10 years, or the primary pathology or 
procedure was too unique.
Procedures
Cases were identified by performing a search of the 
Galaxy electronic operating theatre system for all opera-
tions carried out under a neurosurgical consultant within 
the chosen time periods. Galaxy and the Prescribing 
Information and Communications System were then used 
to collate relevant variables.
Demographic data included age and gender. Opera-
tive data included name of procedure, grade of primary 
surgeon and operative time points. Grade of surgeon 
was defined as junior Senior Registrar (SpR) (ST3–5 or 
equivalent), senior SpR (ST5–8 or equivalent), fellow or 
consultant. Preoperative anaesthetic time was defined 
as time ‘into anaesthetic room’ to ‘knife to skin’, oper-
ative time was defined as ‘knife to skin’ to ‘skin closure’ 
and postoperative anaesthetic time was defined as ‘skin 
closure’ to time ‘into theatre recovery’.
Clinical data included LoS in days, discharge Glasgow 
Outcome Score (GOS),10 30- day mortality, postoperative 
pulmonary complications and COVID-19 swab status. 
Swabs were deemed to be positive if SARS- CoV-2 RNA was 
detected by the standard RT- PCR laboratory test.
COVID-19 swabbing protocols were constantly evolving 
during this early phase of the pandemic as scientific 
knowledge and testing increased. For this reason, there is 
no one single consistent swabbing protocol for the time 




1. 30- day mortality.
2. Postoperative pulmonary complication.
Primary outcomes were designed to be comparable 
with the COVIDSurg study.8 For 30- day mortality, day of 
surgery was treated as day 0. Postoperative pulmonary 
complication was defined as pneumonia, acute respira-
tory distress syndrome or unexpected postoperative 
ventilation (any episode of non- invasive ventilation, inva-
sive ventilation or extracorporeal membrane oxygenation 
after initial extubation after surgery; or patient could not 
be extubated as planned after surgery).
Secondary outcomes
1. Discharge GOS.1–5
2. LoS in hospital (days).
3. Grade of primary surgeon.
4. Preoperative and postoperative anaesthetic time (min-
utes).
5. Operative time (minutes).
The GOS is an objective, functional outcome score 
from 1 to 5.11 Favourable GOS was defined as a score of 
3Toman E, et al. BMJ Open 2021;11:e047063. doi:10.1136/bmjopen-2020-047063
Open access
4 (moderate disability) or 5 (good recovery). Unfavour-
able GOS was defined as a score of 1 (dead), 2 (vegetative 
state) or 3 (severe disability).
Exploratory outcome
COVID-19 status both preoperatively and postoperatively 
and the clinical course of positive patients.
Statistical methods
The study was conducted and reported in line with 
Strengthening the Reporting of Observational Studies in 
Epidemiology guidelines for cohort studies.12 Continuous 
data were tested for normal distribution prior to analysis. 
Parametric data are presented as mean with 95% CI, and 
the unpaired t- test used to detect differences between 
groups. Non- parametric data are presented as median 
with IQR, and Mann- Whitney used to detect differences 
between groups. The X2 test was used for categorical data. 
Missing data points were removed from final analyses. 
Clinical significance was defined as p<0.05.
Analyses were performed using GraphPad Prism soft-
ware V.8.4.3 for Windows.
Patient and public involvement
While there has been significant patient and public 
involvement (PPI) with regard to patient pathways during 
the pandemic, there was no specific PPI consultation for 
this study. This was due to the acutely evolving nature of 
the pandemic, time limits and manpower restraints.
RESULTS
Overall, 231 cases were performed during the initial 
pandemic phase. Of these 17.3% (n=40) were unmatch-
able and so were removed from the final analysis of 
primary and secondary outcomes. A final cohort of 191 
cases from the initial pandemic phase were successfully 
matched to 191 cases from 2019.
The mean age for patients in the pandemic group was 
55 years and the matched group, 54 years. There was no 
statistically significant difference between the age of the 
two cohorts (p=0.795 (95% CI −3.7 to 2.8)). With regard 
to gender, 42.4% (n=81) and 47.6% (n=91) were women 
in the pandemic and matched cohorts, respectively. 
There was no statistically significant difference in gender 
between the two groups (p=0.304).
In terms of theatre location, during the pandemic 
97.4% (n=186) of cases were performed in a dedi-
cated emergency neurosurgical theatre and 2.6% (n=5) 
performed in a shared- specialties emergency theatre. 
Cases from the matched cohort were performed across 
six separate neurosurgery theatres.
Primary outcomes
There was no statistically significant difference in either 
30- day mortality or rates of postoperative pulmonary 
complication between the pandemic and matched 
cohorts (see table 1).
Secondary outcomes
The majority of patients in both groups were discharged 
with a favourable GOS: 89.9% (n=170) and 92.1% (n=176) 
for pandemic and matched cohorts, respectively. There 
was no statistically significant difference in discharge 
GOS between the pandemic and matched cohorts (see 
table 1 and figure 1).
Median LoS was 4.5 days (IQR 2.0–10.3) for the 
pandemic cohort and 6.0 days (IQR 2.0–18.0) for the 
matched cohort. There was no statistically significant 
difference in LoS between pandemic and matched 
cohorts (p=0.25).
There was no statistically significant difference in preop-
erative anaesthetic time, operative time or postoperative 
anaesthetic time between pandemic and matched cohorts 
(see table 2). However, there was a significant difference 
in the variation of grade of primary surgeon between the 
two cohorts. Although the number of cases that consul-
tants performed remained the same, there was a trend 
towards more cases being performed by senior SpRs and 
fellows rather than junior SpRs during the pandemic (see 
table 2).
COVID-19
For this section, all 231 participants for the pandemic 
period were analysed, including the unmatched cases. 
With regard to COVID-19 testing, 60.1% (n=139) were 
swabbed preoperatively and 37.2% (n=86) were swabbed 
postoperatively; some were swabbed both preoperatively 
and postoperatively. Twenty- seven per cent (n=63) of 
cases had neither preoperative nor postoperative swabs. 
Five patients in total tested positive for COVID-19 (see 
table 3 for case details). Four patients with a positive 
COVID-19 swab were operated on in the same theatre.
DISCUSSION
This study has demonstrated that the mortality and 
morbidity of neurosurgical patients undergoing opera-
tive management at UHB was not affected by the initial 






30- day mortality 3.7 (7) 3.1 (6) 0.778
Postop pulmonary 
complications
10.5 (20) 10.5 (20) 1.000
Favourable outcome 
(GOS 4–5)
89.9 (170)* 92.1 (176) 0.366
Unfavourable outcome 
(GOS 1–3)
10.4 (20)* 7.9 (15)
Data are presented as % (n).
*One patient still an inpatient at time of analysis and was not 
included in analysis.
GOS, Glasgow Outcome Score.
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COVID-19 outbreak. The patient selection, preopera-
tive, perioperative and postoperative protocols at UHB 
for neurosurgery during the pandemic have ensured 
the short- term outcome for patients has not significantly 
changed compared with normal practice. During the 
pandemic, all neurosurgical consultants and registrars 
who were part of the on- call rota underwent fit testing for 
FFP3 masks. When operating on patients with unknown 
or pending COVID-19 status, all theatre staff wore FFP3 
mask, protective face- shield/visors or eye- goggles periop-
eratively. When operating on patients with negative 
COVID-19 result, there was no requirement to wear an 
FFP3 mask. However, during intubation and extubation 
in all cases, the anaesthetic team had full personal protec-
tive equipment (PPE) due to high risk of exposure to 
aerosol. In all transsphenoidal surgery cases, all theatre 
staff wore PPE perioperatively. Such protocols and prac-
tices should therefore be reinstated in future pandemic 
waves.
Discussion surrounding how these results may impact 
on practice during this recovery phase of the pandemic 
is more complex. Current guidelines from both the 
National Institute of Health and Care Excellence (NICE) 
and the Royal College of Surgeons England (RCS) 
recommend strict social distancing, swabbing regimes 
and the separation of COVID-19 positive and negative 
patients.13 14 The RCS goes further by stating that every 
hospital should have access to ‘COVID- light sites’ that 
‘might be created at independent hospitals, within desig-
nated areas in National Health Service (NHS) hospitals 
or for an entire hospital functioning as an NHS network 
hub’.15 A recent survey however demonstrated that 
nationally 26% of hospitals have not been able to access 
COVID- light facilities.16
To comply with NICE and RCS guidance, UHB designed 
‘hot’ and ‘cold’ surgical pathways dependant on preop-
erative COVID-19 status. This new strategy was imple-
mented on 1 June 2020 when elective operating restarted. 
Designated hot and cold pathways will increase public 
confidence that the risk of transmission is being reduced 
as much as is physically possible. The downside to having 
separate pathways is the huge logistical organisation they 
require, the associated financial impact of running addi-
tional swabbing, admission and surgical pathways, and a 
greatly reduced theatre capacity at a time where waiting 
lists are the highest they have been for over a decade.17
This study is the first to demonstrate that mixing 
COVID-19 positive, unknown and negative cases in a 
single large centre has not impacted patient outcomes 
during the initial phase of the pandemic. Our data 
suggest that it is not necessary to provide ‘COVID- light 
centres’, and as long as rigorous protocols are adhered to, 
neurosurgical care can proceed with acceptable health-
care outcomes comparable with pre- pandemic practice. 
While this small study does not definitively prove that 
mixing of patients is safe on a national scale, it certainly 
highlights that more investigation is required to support 
or refute these findings. The authors therefore strongly 
recommend that a larger, multicentre study should 
be undertaken during the next stage of the pandemic 
to assess whether outcome and infection rate is truly 
improved by such a costly and time- intensive approach 
to elective surgery.
Figure 1 Comparison of discharge GOS. GOS, Glasgow 
Outcome Score.
Table 2 Comparison of procedure details
Pandemic Matched
P valuen=191 n=191
Grade of primary surgeon 0.0014
  Junior SpR 5.2 (10) 6.3 (12)
  Senior SpR 7.3 (14) 14.7 (28)
  Fellow 9.4 (18) 1.6 (3)
  Consultant 78.0 (149) 77.5 (148)
Preop anaesthetic time 58.5 (44.0–76.0) 57 (46.0–72.0) 0.33
Operative time 101.5 (57.0–150.5) 102 (54.0–148.0) 0.792
Postop anaesthetic time 19 (11.75–28.0) 17 (11.0–24.0) 0.113
Data are presented as % (n) for grade of primary surgeon and median (IQR) for anaesthetic and operative times. Units of time presented are 
minutes.
SpR, Senior Registrar.
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It may seem intuitive that by increasing the amount 
of PPE anaesthetic and surgical teams must wear, the 
anaesthetic and operative time should also increase. 
Unpublished data from UHB analysing neuro- oncology 
operations during the first month of initial phase of the 
pandemic suggested that the average length of opera-
tion was significantly increased. However, our study has 
demonstrated that there was no significant difference in 
the length of operation or anaesthetic when compared 
with normal practice. It must be noted however that 
although actual times for anaesthetic and procedure 
have not been impacted, turnaround time between cases 
has anecdotally increased at UHB. This is due to an addi-
tional 15- minute theatre ventilation air change prior to 
each new case, supplementary cleaning protocols and the 
removal of the communal ‘holding bay’ prior to surgery. 
These data were not available retrospectively and so 
should be included in any future prospective study when 
analysing length of theatre time and planning realistic 
theatre lists.
The only statistically significant finding in this study 
was a difference in the grade of primary surgeon. 
Although there was no difference in the proportion of 
patients operated on by a consultant, there was a shift 
towards seniority among operations performed by non- 
consultants. During the pandemic, more operations were 
primarily performed by senior SpRs and fellows than 
junior SpRs compared with normal practice. One reason 
for this may be that initially, more junior SpRs and senior 
house officers were redeployed to Intensive Care Unit and 
proning teams compared with senior SpRs. These data 
add to the growing body of evidence that COVID-19 has 
negatively impacted on surgical training in the UK.18 19 
A UK- wide survey of neurosurgery trainees revealed that 
fewer training cases were available due to cancellation 
of elective lists, surgical rotations were halted, examina-
tions cancelled and nationally there was an increase in 
out- of- hours work during the height of the pandemic.20 
Training is also a factor that must be considered in the 
recommencement of elective surgery15 and should be 
included in any future study addressing the recovery of 
surgical services.
In summary, the mortality, morbidity and functional 
outcome of patients undergoing neurosurgical opera-
tions at UHB have not been affected by the COVID-19 
pandemic. To the best of the authors’ knowledge, this 
is the first study to match neurosurgical cases from the 
initial pandemic phase to pre- pandemic cases. Most of 
the surgical- related evidence up until now has focused on 
outcomes in patients with confirmed COVID-19. We must 
not forget however that the majority of surgical patients 
do not have COVID-19 and it is imperative that outcomes 
are studied in this group to help design evidence- based 
surgical pathways for the remainder of this national and 
global health disaster. This study is based on data from 
a single centre and focuses on neurosurgery patients 
only. Given the variation in national practices, we would 
encourage individual hospitals and Trusts to analyse 
outcomes in the same way. This would provide larger 
datasets and could identify which protocols have been 
most effective. In particular, it is important to ascertain 
whether mixing positive, unknown and negative cases 
in a shared surgical pathway is detrimental. If not, the 
national implementation of COVID- light sites should be 
called into question as these currently limit patient flow 
in a time of waiting list crisis.
Limitations
All matched cohort studies recognise the limitations 
of matching cases as not all variables can be taken into 
account. For a COVID-19 study in particular, we recognise 
that ethnicity21 and body mass index22 are contributing 
factors to morbidity and mortality and these variables 
were not matched.
The sample size included in this analysis is relatively 
small and so may be underpowered. Larger studies and 
meta- analysis would provide further data to support or 
refute these findings.
During the pandemic period, the UHB swabbing 
protocol evolved and as a result was not consistent across 
the whole study period. While a true reflection of our 













A Positive Positive Pneumonia Survived 4 23
B Positive Positive Pneumonia Survived 4 23
C Not swabbed Positive Nil Survived 5 22
D Negative Positive Nil Survived 5 6
E Negative Positive Unexpected postop 
ventilation
Survived* 1 RIP day 
42
*Patient died at day 42 following admission (day 38 postop); immunocompromised individual with COVID-19 pneumonia listed as contributory 
factor as cause of death.
GOS, Glasgow Outcome Score.
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clinical practice this, along with the small number of 
COVID-19 positive patients, means that it is unsuitable 
to perform inferential statistics on these data. However, 
the authors felt it important to include descriptive data 
for the COVID-19 positive patients to enable inclusion 
in any future meta- analysis or power calculations.
CONCLUSION
During the initial phase of the COVID-19 pandemic, 
the mortality, morbidity and functional outcomes of 
operatively managed neurosurgery patients were not 
significantly affected compared with normal prac-
tice. Although anaesthetic and operative time was not 
altered, the grade of primary surgeon was significantly 
more senior which is likely to have negatively impacted 
on training opportunities for junior surgeons. This 
adds to the growing body of evidence that surgical 
training in the UK has been significantly affected by 
the pandemic. Mixing COVID-19 positive, unknown 
and negative cases did not significantly impact the 
outcomes of neurosurgical patients and calls into ques-
tion the need for COVID- light sites. Larger multicentre 
studies are needed to confirm or refute these findings 
and collect prospective data to support the implemen-
tation of evidence- based surgical pathways now that we 
are entering the next wave of the pandemic.
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